University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Thomas Hope, MD

Thomas Hope, MD

Assistant Professor, Abdominal Imaging and Nuclear Medicine, UCSF

Cancer Center Program Memberships

Prostate Cancer

Research Summary

My research program is focused on imaging cancer using MRI and novel PET tracers. At UCSF, I have developed the gallium-68 DOTA-TOC imaging program for neuroendocrine tumor staging, and am the principle investigator on the FDA IND. I have also successfully brought Ga-68 PSMA imaging to UCSF and am currently drafting the IND submission to allow for the evaluation of the clinical use of this agent. I am interested in using somatostatin receptor and PSMA based PET agents in order to distinguish neuroendocrine prostate cancer from adenocarcinoma. Additionally, I believe that the combination of MR and PET parameters will aid in the staging of cancers. Most straightforward is a study we are carrying out in low risk prostatectomy patients where we are evaluating the use of PET/MRI using Ga-68 PSMA and MR imaging of the primary tumor. In the setting of patients with metastatic disease, PET/MRI will likely have an even more important role, as response to treatment will change uptake of non-FDG tracers in ways that are not immediately clear and intepretation will likely rely on changes in MR imaging parameters such as diffusion weighted imaging (DWI).

Education

Duke University, Durham, NC, BA/BS, 6/2001, Biology, Economics
Stanford University, MD, 6/2007 Medicine
Kaiser San Francisco, 6/2008, Internal Medicine
University of California, San Francisco, 6/2012, Diagnostic Radiology Residency
Stanford University, 6/2013, Body MRI/nuclear medicine Fellowship


Professional Experience

  • 2007-2008
    Intern, Department of Medicine, Kaiser San Francisco, CA
  • 2008-2012
    Resident, Department of Radiology and Biomedical Imaging, UCSF, San Francisco, CA
  • 2012-2013
    Fellow, Department of Radiology, Stanford University, Stanford, CA
  • 2013-present
    Assistant Professor, Department of Radiology, UCSF, San Francisco, CA

Honors & Awards

  • 2001
    Summa Cum Laude, Duke University
  • 2001
    Phi Beta Kappa, Duke University
  • 2006
    Trainee Research Prize, Radiological Society of North America
  • 2007
    W. S. Moore Award, Nominee, International Society of Magnetic Resonance in Medicine
  • 2011
    Magnum Cum Laude Merit Award, International Society of Magnetic Resonance in Medicine
  • 2012
    Roentgen Resident/Fellow Research Award, Radiological Society of North America
  • 2012
    Alexander Margulis Society Excellence in Research Award, UCSF
  • 2014
    Wylie J. Dodds Research Award, Society of Abdominal Radiology

Selected Publications

  1. Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, Nguyen HG, Reiter RE, Rettig MB, Okamoto S, Emmett L, Zacho HD, Ilhan H, Wetter A, Rischpler C, Schoder H, Burger IA, Gartmann J, Smith R, Small EJ, Slavik R, Carroll PR, Herrmann K, Czernin J, Hope TA. Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. JAMA Oncol. 2019 Mar 28.
    View on PubMed
  2. Boreta L, Gadzinski AJ, Wu SY, Xu M, Greene K, Quanstrom K, Nguyen HG, Carroll PR, Hope TA, Feng FY. Location of recurrence by Gallium-68 PSMA-11 PET scan in prostate cancer patients eligible for salvage radiotherapy. Urology. 2019 Mar 27.
    View on PubMed
  3. Hope TA, Calais J, Zhang L, Dieckmann W, Millo C. 111In-pentetreotide scintigraphy vs. 68Ga-DOTATATE PET: Impact on Krenning Scores and Effect of Tumor Burden. J Nucl Med. 2019 Mar 08.
    View on PubMed
  4. Gambhir SS, Shankar LK, Rosenthal E, Warram JM, Ghesani MV, Hope TA, Jacobs PM, Jacobson GB, Wilson T, Siegel BA. Proceedings - Pathways for Successful Translation of New Imaging Agents and Modalities: Phase III Studies. J Nucl Med. 2019 Mar 08.
    View on PubMed
  5. Wu SY, Feng FY, Hope TA. AUTHOR REPLY. Urology. 2019 Mar; 125:161-162.
    View on PubMed
  6. Kim S, Dillon WP, Hope TA, El-Sayed IH, van Zante A, Wu K, Masharani U. Ectopic thyroid-stimulating hormone-secreting pituitary adenoma of the nasopharynx diagnosed by 68Ga-DOTA-TATE PET/CT. World Neurosurg. 2019 Feb 21.
    View on PubMed
  7. Perez PM, Hope TA, Behr SC, van Zante A, Small EJ, Flavell RR. Intertumoral Heterogeneity of 18F-FDG and 68Ga-PSMA Uptake in Prostate Cancer Pulmonary Metastases. Clin Nucl Med. 2019 Jan; 44(1):e28-e32.
    View on PubMed
  8. Wu SY, Boreta L, Shinohara K, Nguyen H, Gottschalk AR, Hsu IC, Roach M, Westphalen AC, Feng FY, Carroll PR, Chang AJ, Hope TA. Impact of Staging 68Ga-PSMA-11 PET Scans on Radiation Treatment Plansin Patients With Prostate Cancer. Urology. 2019 Mar; 125:154-162.
    View on PubMed
  9. Wu SY, Feng FY, Hope TA. WITHDRAWN: PSMA-PET: a maturing tool. Urology. 2018 Dec 20.
    View on PubMed
  10. Hope TA, Goodman JZ, Allen IE, Calais J, Fendler WP, Carroll PR. Meta-analysis of 68Ga-PSMA-11 PET Accuracy for the Detection of Prostate Cancer Validated by Histopathology. J Nucl Med. 2018 Dec 07.
    View on PubMed
  11. Behr SC, Aggarwal R, Van Brocklin HF, Flavell RR, Geo K, Small EJ, Blecha J, Jivan S, Hope TA, Simko JP, Kurhanewicz J, Noworolski SM, Korn NJ, De Los Santos R, Cooperberg MR, Carroll PR, Nguyen HG, Greene KL, Langton-Webster B, Berkman CE, Seo Y. First-in-Human Phase I study of CTT1057, a Novel 18F Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate Specific Membrane Antigen in Prostate Cancer. J Nucl Med. 2018 Nov 21.
    View on PubMed
  12. Miyahira AK, Den RB, Carlo MI, de Leeuw R, Hope TA, Karzai F, McKay RR, Salami SS, Simons JW, Pienta KJ, Soule HR. Tumor cell heterogeneity and resistance; report from the 2018 Coffey-Holden Prostate Cancer Academy Meeting. Prostate. 2019 Feb; 79(3):244-258.
    View on PubMed
  13. Hicks RM, Simko JP, Westphalen AC, Nguyen HG, Greene KL, Zhang L, Carroll PR, Hope TA. Diagnostic Accuracy of 68Ga-PSMA-11 PET/MRI Compared with Multiparametric MRI in the Detection of Prostate Cancer. Radiology. 2018 Dec; 289(3):730-737.
    View on PubMed
  14. Yang J, Liu J, Wiesinger F, Menini A, Zhu X, Hope TA, Seo Y, Larson PEZ. Developing an efficient phase-matched attenuation correction method for quiescent period PET in abdominal PET/MRI. Phys Med Biol. 2018 Sep 10; 63(18):185002.
    View on PubMed
  15. Polverari G, Ceci F, Allen-Auerbach M, Gupta P, Fishbein MC, Reiter RE, Lee JM, Hope TA, Carroll RM, Czernin J, Calais J. Solitary Mucinous Prostate Adenocarcinoma Lung Metastasis Detected by 68Ga-PSMA-11 PET/CT. Clin Genitourin Cancer. 2018 Sep 07.
    View on PubMed
  16. Bailey JJ, Jordan EJ, Burke C, Ohliger MA, Wang ZJ, Van Loon K, Varma MG, Hope TA. Does Extended PET Acquisition in PET/MRI Rectal Cancer Staging Improve Results? AJR Am J Roentgenol. 2018 10; 211(4):896-900.
    View on PubMed
  17. Mallak N, Hope TA, Guimaraes AR. PET/MR Imaging of the Pancreas. Magn Reson Imaging Clin N Am. 2018 Aug; 26(3):345-362.
    View on PubMed
  18. Fraum TJ, Ludwig DR, Kim EH, Schroeder P, Hope TA, Ippolito JE. Prostate cancer PET tracers: essentials for the urologist. Can J Urol. 2018 Aug; 25(4):9371-9383.
    View on PubMed
  19. Afshar-Oromieh A, Debus N, Uhrig M, Hope TA, Evans MJ, Holland-Letz T, Giesel FL, Kopka K, Hadaschik B, Kratochwil C, Haberkorn U. Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer. Eur J Nucl Med Mol Imaging. 2018 11; 45(12):2045-2054.
    View on PubMed
  20. Fraum TJ, Ludwig DR, Hope TA, Fowler KJ. PET/MRI for Gastrointestinal Imaging: Current Clinical Status and Future Prospects. Gastroenterol Clin North Am. 2018 09; 47(3):691-714.
    View on PubMed

Go to UCSF Profiles, powered by CTSI